56
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Plasmodium falciparum K13 mutations in Africa and Asia impact artemisinin resistance and parasite fitness

      research-article
      1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 2 , 1 , 1 , 1 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 3 , 21 ,
      ,
      eLife
      eLife Sciences Publications, Ltd
      Plasmodium falciparum, malaria, artemisinin resistance, CRISPR/Cas9, ring-stage survival, fitness, P. falciparum

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The emergence of mutant K13-mediated artemisinin (ART) resistance in Plasmodium falciparum malaria parasites has led to widespread treatment failures across Southeast Asia. In Africa, K13-propeller genotyping confirms the emergence of the R561H mutation in Rwanda and highlights the continuing dominance of wild-type K13 elsewhere. Using gene editing, we show that R561H, along with C580Y and M579I, confer elevated in vitro ART resistance in some African strains, contrasting with minimal changes in ART susceptibility in others. C580Y and M579I cause substantial fitness costs, which may slow their dissemination in high-transmission settings, in contrast with R561H that in African 3D7 parasites is fitness neutral. In Cambodia, K13 genotyping highlights the increasing spatio-temporal dominance of C580Y. Editing multiple K13 mutations into a panel of Southeast Asian strains reveals that only the R561H variant yields ART resistance comparable to C580Y. In Asian Dd2 parasites C580Y shows no fitness cost, in contrast with most other K13 mutations tested, including R561H. Editing of point mutations in ferredoxin or mdr2, earlier associated with resistance, has no impact on ART susceptibility or parasite fitness. These data underline the complex interplay between K13 mutations, parasite survival, growth and genetic background in contributing to the spread of ART resistance.

          Related collections

          Most cited references66

          • Record: found
          • Abstract: found
          • Article: not found

          A molecular marker of artemisinin-resistant Plasmodium falciparum malaria.

          Plasmodium falciparum resistance to artemisinin derivatives in southeast Asia threatens malaria control and elimination activities worldwide. To monitor the spread of artemisinin resistance, a molecular marker is urgently needed. Here, using whole-genome sequencing of an artemisinin-resistant parasite line from Africa and clinical parasite isolates from Cambodia, we associate mutations in the PF3D7_1343700 kelch propeller domain ('K13-propeller') with artemisinin resistance in vitro and in vivo. Mutant K13-propeller alleles cluster in Cambodian provinces where resistance is prevalent, and the increasing frequency of a dominant mutant K13-propeller allele correlates with the recent spread of resistance in western Cambodia. Strong correlations between the presence of a mutant allele, in vitro parasite survival rates and in vivo parasite clearance rates indicate that K13-propeller mutations are important determinants of artemisinin resistance. K13-propeller polymorphism constitutes a useful molecular marker for large-scale surveillance efforts to contain artemisinin resistance in the Greater Mekong Subregion and prevent its global spread.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Spread of artemisinin resistance in Plasmodium falciparum malaria.

            Artemisinin resistance in Plasmodium falciparum has emerged in Southeast Asia and now poses a threat to the control and elimination of malaria. Mapping the geographic extent of resistance is essential for planning containment and elimination strategies. Between May 2011 and April 2013, we enrolled 1241 adults and children with acute, uncomplicated falciparum malaria in an open-label trial at 15 sites in 10 countries (7 in Asia and 3 in Africa). Patients received artesunate, administered orally at a daily dose of either 2 mg per kilogram of body weight per day or 4 mg per kilogram, for 3 days, followed by a standard 3-day course of artemisinin-based combination therapy. Parasite counts in peripheral-blood samples were measured every 6 hours, and the parasite clearance half-lives were determined. The median parasite clearance half-lives ranged from 1.9 hours in the Democratic Republic of Congo to 7.0 hours at the Thailand-Cambodia border. Slowly clearing infections (parasite clearance half-life >5 hours), strongly associated with single point mutations in the "propeller" region of the P. falciparum kelch protein gene on chromosome 13 (kelch13), were detected throughout mainland Southeast Asia from southern Vietnam to central Myanmar. The incidence of pretreatment and post-treatment gametocytemia was higher among patients with slow parasite clearance, suggesting greater potential for transmission. In western Cambodia, where artemisinin-based combination therapies are failing, the 6-day course of antimalarial therapy was associated with a cure rate of 97.7% (95% confidence interval, 90.9 to 99.4) at 42 days. Artemisinin resistance to P. falciparum, which is now prevalent across mainland Southeast Asia, is associated with mutations in kelch13. Prolonged courses of artemisinin-based combination therapies are currently efficacious in areas where standard 3-day treatments are failing. (Funded by the U.K. Department of International Development and others; ClinicalTrials.gov number, NCT01350856.).
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda

              Artemisinin resistance (delayed P. falciparum clearance following artemisinin-based combination therapy), is widespread across Southeast Asia but to date has not been reported in Africa 1–4 . Here we genotyped the P. falciparum K13 (Pfkelch13) propeller domain, mutations in which can mediate artemisinin resistance 5,6 , in pretreatment samples collected from recent dihydroarteminisin-piperaquine and artemether-lumefantrine efficacy trials in Rwanda 7 . While cure rates were >95% in both treatment arms, the Pfkelch13 R561H mutation was identified in 19 of 257 (7.4%) patients at Masaka. Phylogenetic analysis revealed the expansion of an indigenous R561H lineage. Gene editing confirmed that this mutation can drive artemisinin resistance in vitro. This study provides evidence for the de novo emergence of Pfkelch13-mediated artemisinin resistance in Rwanda, potentially compromising the continued success of antimalarial chemotherapy in Africa.
                Bookmark

                Author and article information

                Contributors
                Role: Reviewing Editor
                Role: Senior Editor
                Journal
                eLife
                Elife
                eLife
                eLife
                eLife Sciences Publications, Ltd
                2050-084X
                19 July 2021
                2021
                : 10
                : e66277
                Affiliations
                [1 ]Department of Microbiology and Immunology, Columbia University Irving Medical Center New YorkUnited States
                [2 ]Department of Microbiology and Immunology, University of Otago DunedinNew Zealand
                [3 ]Malaria Genetics and Resistance Unit, Institut Pasteur, INSERM U1201, CNRS ERL9195 ParisFrance
                [4 ]Institut Cochin, INSERM U1016, Université Paris Descartes ParisFrance
                [5 ]Department of Genetics, University of North Carolina at Chapel Hill Chapel HillUnited States
                [6 ]Programme National de Lutte Contre le Paludisme au Tchad NdjamenaChad
                [7 ]Centre National de Recherche et de Formation sur le Paludisme OuagadougouBurkina Faso
                [8 ]Laboratoire de Parasitologie, Institut Pasteur de Bangui BanguiCentral African Republic
                [9 ]University Teaching Hospital of Kamenge BujumburaBurundi
                [10 ]Ifakara Health Institute Dar es SalaamUnited Republic of Tanzania
                [11 ]Malaria and Other Parasitic Diseases Division, Rwanda Biomedical Centre KigaliRwanda
                [12 ]National Malaria Control Program FreetownSierra Leone
                [13 ]National Malaria Control Program BanjulGambia
                [14 ]Programme National de Lutte Contre le Paludisme BrazzavilleDemocratic Republic of the Congo
                [15 ]School of Public Health and Community Medicine, University of Gothenburg GothenburgSweden
                [16 ]National Center for Parasitology, Entomology & Malaria Control Phnom PenhCambodia
                [17 ]Shoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University Mae SotThailand
                [18 ]Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford OxfordUnited Kingdom
                [19 ]Texas Biomedical Research Institute San AntonioUnited States
                [20 ]Department of Medicine, University of California, San Francisco San FranciscoUnited States
                [21 ]Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center New YorkUnited States
                University of Geneva Switzerland
                University of Geneva Switzerland
                University of Geneva Switzerland
                Author information
                https://orcid.org/0000-0001-9519-487X
                http://orcid.org/0000-0002-4149-4030
                http://orcid.org/0000-0002-9605-0154
                http://orcid.org/0000-0002-5266-8243
                http://orcid.org/0000-0002-3614-436X
                http://orcid.org/0000-0003-2923-6060
                http://orcid.org/0000-0002-2980-0429
                http://orcid.org/0000-0002-7951-0745
                https://orcid.org/0000-0001-6753-8938
                Article
                66277
                10.7554/eLife.66277
                8321553
                34279219
                f17c57f3-14a8-4cc9-b1ef-79bed2ffe924
                © 2021, Stokes et al

                This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

                History
                : 05 January 2021
                : 17 July 2021
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/100000060, National Institute of Allergy and Infectious Diseases;
                Award ID: R01 AI109023
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/100000005, U.S. Department of Defense;
                Award ID: W81XWH1910086
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/100000865, Bill and Melinda Gates Foundation;
                Award ID: OPP1201387
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/100004440, Wellcome Trust;
                Award ID: 106698
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/100000060, National Institute of Allergy and Infectious Diseases;
                Award ID: R37 AI048071
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/100000060, National Institute of Allergy and Infectious Diseases;
                Award ID: T32 AI106711
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/100004423, World Health Organization;
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/100000060, National Institute of Allergy and Infectious Diseases;
                Award ID: R01 AI075045
                Award Recipient :
                The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
                Categories
                Research Article
                Epidemiology and Global Health
                Microbiology and Infectious Disease
                Custom metadata
                Plasmodium falciparum K13 mutations confer resistance to the antimalarial artemisinin in Asian and African parasites, with most gene-edited mutant K13 African parasite lines showing a fitness cost that may predict slow dissemination of artemisinin resistance in high-transmission settings.

                Life sciences
                plasmodium falciparum,malaria,artemisinin resistance,crispr/cas9,ring-stage survival,fitness,p. falciparum

                Comments

                Comment on this article